Tumors that had initial high uptake of the CD3 radiopharmaceutical later had reduced tumor volume, with the authors concluding that higher initial radiopharmaceutical uptake was indicative of more T cell infiltration and heralded potential anti-CTLA-4 mediated ICI response (57). The gene discussed is CTLA4; the disease is neoplasm.